Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course.

Patients with Visceral Metastases Receiving Trastuzumab Therapy Predict the Clinical Course, Thomas Schöndorf, Markus Hoopmann, Mathias Warm, Rainer Neumann, Anke Thomas, Uwe-Jochen Göhring, Carsten Eisberg, and Peter Mallmann ( Department of Gynecology and Obstetrics, University of Cologne, 50924 Cologne, Germany; 2 Bayer Vital, 51368 Leverkusen, Germany; * both authors contributed equally to this work; † address correspondence to this author at: Department of Gynecology and Obstetrics, University of Cologne, Kerpener Strasse 34, 50924 Cologne, Germany; fax 49-221-478-7495, e-mail [email protected])